VRCA,Verrica Pharmaceuticals Inc. | Healthcare

Healthcare

VRCA

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Verrica Pharmaceuticals Inc.VRCA

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States.

The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts.

The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.

Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Latest News >

Cannae, KDSA to Buy Majority Stake in The Watkins Company

Oct 7, 2024

04:59 PM EDT, 10/07/2024 (MT Newswires) -- Cannae Holdings ( CNNE ) and KDSA Investment Partners said Monday they have agreed to buy a majority stake in The Watkins Company, a flavoring products company. The current majority owner and Chairman, Mark Jacobs, will roll a significant equity stake into the transaction, the companies said. They expect to close the deal...

Japan's Nikkei falls after Wall Street's weak finish

Oct 7, 2024

TOKYO, Oct 8 (Reuters) - Japan's Nikkei share average retreated on Tuesday, weighed down by Wall Street's weak finish overnight and rising U.S. yields on reduced bets of another large rate cut following Friday's strong jobs report. The Nikkei was down 0.8% at 39,016.79, as of 0008 GMT, after closing 1.8% higher on Monday. The broader Topix was down 0.98%...

PRECIOUS-Gold flat as markets await Fed minutes

Oct 7, 2024

Oct 8 (Reuters) - Gold prices were flat in early Asian hours on Tuesday as market participants awaited minutes of the U.S. Federal Reserve's last meeting and more economic data for further clarity on policy easing this year. FUNDAMENTALS * Spot gold was little changed at $2,643.68 per ounce, as of 0013 GMT. U.S. gold futures fell 0.1% to $2,662.90....

Samsung's Q3 profit misses estimates as it struggles in AI chips

Oct 7, 2024

SEOUL, Oct 8 (Reuters) - Samsung Electronics ( SSNLF ) estimated on Tuesday its third-quarter operating profit jumped 274%, but that was short of analysts' estimates as the tech giant struggled to capitalise on strong demand for chips used in artificial intelligence servers. The world's largest memory chip, smartphone and TV maker estimated an operating profit of 9.1 trillion won...